Who can participate?
Diagnosis of 1 of the Following:
Histologically confirmed relapsed or refractory solid tumors at original diagnosis including CNS tumors* (Part 1 and Part 2a)
- Neurologic deficits in patients with CNS tumors must have been relatively stable for ≥1 week
- Histologically confirmed soft tissue sarcoma, desmoplastic small round cell tumor, or extraosseous Ewing sarcoma at original diagnosis including the following (Part 2b):
- Tumor in the head, neck, or extremity or fixed within the abdomen or pelvis that it is not sensitive to motion artifact
- No isolated pulmonary metastases
- Slides or tissue blocks from either initial diagnosis or relapse must be available for central review
- NOTE: Histologic confirmation not required for intrinsic brain stem cell tumor, optic pathway gliomas, pineal tumors and elevations of cerebrospinal fluid, and serum tumor markers including alpha-fetoprotein or beta-human chorionic gonadotropin.
- Disease with no known curative therapy or no therapy proven to prolong survival with acceptable quality of life
- Measurable or evaluable disease (Part 1 and Part 2a)
- Measurable tumor that is ≥2 cm in its longest diameter (Part 2b)
- Patients must be:
- > 2 years of age and ≤21 years of age (Part 1 and Part 2a)
- > 2 years of age and ≤25 years of age (Part 2b)
- Body surface area ≥0.48 m2 (Part 1 and Part 2b)
- For patients with CNS tumors or CNS metastasis, there must be no evidence of new CNS hemorrhage of more than punctate size and/or > 3 foci of punctate hemorrhage on baseline MRI for primary CNS tumors ≥14 days prior to study entry
What will happen in the study?
This is a multicenter study.
Patients receive oral pazopanib hydrochloride (Part 1 and Part 2a) once daily on days 1-28. Courses repeat every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Patients accrued after the maximum-tolerated dose (MTD) of pazopanib hydrochloride has been determined receive pazopanib hydrochloride as either an oral suspension or in its standard oral form. (Part 2b)
Some patients undergo dynamic contrast-enhanced MRI at baseline and periodically during study.
Blood samples are collected at baseline and periodically during study for pharmacokinetic studies.